Catalog No.
DHC21098
Description
Tusamitamab-MMAE is an ADC consisting of a CEACAM5-directed antibody and Monomethyl auristatin E (MMAE) used for the study of non-small cell lung cancer.
Species reactivity
Human
Clonality
Monoclonal
Target
CEACAM5
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Applications
Research Grade Biosimilar
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Tusamitamab-MMAE
Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors., PMID:40413667
Artificial intelligence prediction of carcinoembryonic antigen structure and interactions relevant for colorectal cancer., PMID:40330074
[Diffuse interstitial lung disease induced by antibody-drug conjugates]., PMID:40263022
Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors., PMID:39477960
Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach., PMID:37964462
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape., PMID:37660479
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens., PMID:37645622
'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review., PMID:37185443
Antibodies to watch in 2023., PMID:36472472
Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study., PMID:35191618
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate., PMID:35166967
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study., PMID:35026412
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors., PMID:33046521
For research use only. Not for human or drug use.
